Webinar Alert! Assessing the Use of Non-Human Primates in Translational Research Today Register Today!
Selecting the Optimal Gene Editing Platform
EXECUTIVE SUMMARY
Selecting the Optimal Gene Editing Platform
Selecting the Optimal Gene Editing Platform: Prime vs. Base Editors
CELL & GENE | RNA | BIOLOGICS
Selecting the appropriate gene editing platform is a foundational decision that dictates the entire preclinical and CMC strategy for a therapeutic program. Base editors offer a direct approach for precise single-nucleotide conversions, while prime editors provide a more versatile toolkit for a wider range of edits, including all point mutations and small insertions or deletions. The choice directly impacts payload complexity, the design of the non-viral delivery system (e.g., LNP), and the scope of the bioanalytical characterization required to achieve regulatory acceptance for IND submissions.
What are the primary IND-enabling considerations when choosing between prime and base editors?
The key considerations for an IND-enabling program involve a trade-off between editing versatility and payload complexity. Base editors, with their smaller cargo size, can simplify LNP formulation and manufacturing. Prime editors, while more versatile, require delivery of a larger ribonucleoprotein complex, which places greater demands on the CMC process and requires more extensive characterization of the final product to satisfy global regulators like the FDA and EMA.
How does the delivery system, like a lipid nanoparticle (LNP), impact the preclinical development of a gene editing therapeutic?
The LNP delivery system is integral to therapeutic success. Its composition dictates tissue tropism, delivery efficiency, and the overall safety profile. Advanced formulations, such as those using biodegradable or branched ionizable lipids, are designed to improve endosomal escape and ensure the editing machinery reaches its target inside the cell. A robust preclinical program must evaluate the LNP’s biodistribution, pharmacokinetics, and potential immunogenicity in relevant in vivo models.
Can Franklin Biolabs support the complex bioanalytical assays required for gene editing programs targeting international regulatory submissions?
Yes. Our scientific team develops and validates custom, phase-appropriate bioanalytical assays to measure on-target editing efficiency and quantify off-target events with high sensitivity. This includes NGS-based methods and cellular assays performed under GxP conditions, generating the robust data packages required for harmonized IND and IMPD submissions. Our >100,000 sq ft facility is equipped for these complex analytical programs.
Aligning Editor Selection with Preclinical and CMC Requirements.
The progression beyond first-generation CRISPR-Cas9 systems has introduced powerful tools for precision genome engineering. Base and prime editors operate without inducing widespread double-stranded breaks, significantly mitigating the risks associated with uncontrolled cellular repair pathways. The selection between these platforms is a strategic decision contingent on the specific genetic correction required, the target tissue, and the CMC pathway.
A standard preclinical template does not apply to these advanced therapeutics. A data-driven strategy, tailored to the modality, is required to navigate the path to a successful IND submission.
Comparative Analysis: Mechanism and Application
The functional differences between base and prime editors directly influence their suitability for a given therapeutic application. Base editors function as molecular pencils, erasing and rewriting a single nucleotide. Prime editors act more like a genetic search-and-replace function, offering greater flexibility.
| Feature | Base Editors (e.g., ABE, CBE) | Prime Editors (PE) |
|---|---|---|
| Mechanism | Direct enzymatic conversion of a single DNA base (e.g., C•G to T•A) via a deaminase fused to a Cas9 nickase. | A Cas9 nickase fused to a reverse transcriptase uses a prime editing guide RNA (pegRNA) to directly synthesize edited DNA at the target site. |
| Editing Scope | Limited to specific base transitions (4 of 12 possible). | Capable of all 12 possible point mutations, plus small insertions and deletions. |
| Off-Target Profile | Reduced risk of double-stranded breaks. Potential for “bystander” edits on nearby bases within the activity window. | High fidelity with minimal bystander activity and very low off-target editing rates. |
| Payload Complexity | Smaller and less complex system (Cas9 nickase, deaminase, gRNA). | Larger and more complex system (Cas9 nickase, reverse transcriptase, pegRNA). |
Delivery System Interdependencies
The efficacy of any gene editing platform is contingent upon its successful delivery to the target cell nucleus. For in vivo applications, lipid nanoparticles have become a primary non-viral vector. The size and complexity of the editor payload directly influence LNP formulation. The larger ribonucleoprotein complex of a prime editor, for example, demands a highly optimized LNP to ensure stability and efficient endosomal escape.
The expertise of our scientific leadership, demonstrated through work including our collaboration with Moderna, provides a deep understanding of LNP technology. Research into novel lipid architectures, such as biodegradable ionizable lipids (PMID: 40060499) and branched endosomal disruptor lipids (PMID: 39856035), shows how advanced formulation chemistry can overcome delivery barriers for complex mRNA and ribonucleoprotein payloads. This expertise informs our consultative approach to de-risking LNP-mediated delivery for gene editing programs.
A Coordinated Path to IND
Franklin Biolabs integrates CMC and preclinical development into a unified strategy. This approach is informed by the track record of our core scientific team, which has contributed to a 100% successful IND rate since 2019, well before our formal launch in 2024. By aligning vector analytics with the requirements of IND-enabling toxicology studies, we help sponsors move candidates toward IND within an 18-24 month timeline. Our comprehensive services are detailed within our Vector | CMC | Analytics Services hub.
This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.